Retatrutide activates three metabolic receptors simultaneously — GIP, GLP-1, and glucagon. Understanding how that triple mechanism works, and specifically what the glucagon co-agonism adds, is the key to understanding why this compound has produced the largest weight reduction numbers in Phase 2 clinical data to date.
GLP-3 RT is Evo Peptides' research catalog designation for Retatrutide — a once-weekly injectable peptide developed by Eli Lilly & Company that simultaneously activates three receptors in the incretin and glucagon hormone system: GIP (glucose-dependent insulinotropic polypeptide) receptor, GLP-1 (glucagon-like peptide-1) receptor, and glucagon receptor.
An agonist is a compound that activates a receptor. A triple agonist activates three receptor types. Retatrutide's innovation is combining GIP/GLP-1 dual agonism (the same mechanism as tirzepatide/GLP-2 TRZ) with additional glucagon receptor activation — the third receptor target that prior incretin drugs avoided because of the risk of raising blood glucose.
The compound is under active Phase 3 clinical investigation for obesity, type 2 diabetes management, and metabolic dysfunction-associated steatohepatitis (MASH, also called metabolic fatty liver disease). Retatrutide is not FDA-approved as of 2026 and is available for research use only.
The incretin drug class has progressed through successive generations of receptor targeting complexity. Understanding where GLP-3 RT sits in that progression helps clarify what the additional mechanism adds.
The addition of glucagon receptor agonism is the feature that makes GLP-3 RT research most interesting to metabolic researchers — and the mechanism that was historically most avoided in incretin drug design.
Glucagon is a catabolic hormone released by pancreatic alpha cells in response to low blood glucose. Its primary action is to stimulate hepatic glucose output — raising blood sugar. In diabetic patients, glucagon is typically elevated and contributes to hyperglycemia. Historically, this made glucagon receptor agonism a non-starter for metabolic drug development: activating glucagon receptors would worsen the very condition you're trying to treat.
GLP-1 receptor agonism strongly suppresses glucagon secretion and hepatic glucose output. When glucagon receptor agonism is combined with GLP-1 agonism in the same molecule, the glucose-raising effects of glucagon activation are counteracted by the glucose-suppressing effects of GLP-1 activation. This allows the energy expenditure benefits of glucagon receptor activation to occur without the hyperglycemic cost.
Glucagon receptor activation increases energy expenditure through several pathways including thermogenesis in brown adipose tissue and enhanced hepatic fat oxidation. These mechanisms are additive to — and distinct from — the appetite suppression and satiety signaling driven by GLP-1 and GIP agonism. The hypothesis in GLP-3 RT's design is that combining all three mechanisms produces greater weight reduction than any two can achieve alone.
The Phase 2 data appears to support this hypothesis, with the ~24% mean weight reduction at the highest dose exceeding what dual agonism achieved in Phase 3.
One of the research areas where GLP-3 RT's triple mechanism may offer particular advantages is MASH (metabolic dysfunction-associated steatohepatitis) — a condition involving hepatic fat accumulation, inflammation, and progressive fibrosis.
The glucagon receptor component is hypothesized to be especially relevant here: glucagon receptor activation promotes hepatic fat oxidation, directly addressing hepatic lipid accumulation through a mechanism beyond what GLP-1 agonism alone can achieve. Phase 2 data showed significant reductions in liver fat content as measured by MRI-based fat fraction quantification in participants treated with GLP-3 RT. Dedicated Phase 3 MASH trials are ongoing.
| Parameter | Detail |
|---|---|
| Trial type | Phase 2, double-blind, placebo-controlled, dose-ranging |
| Duration | 48 weeks |
| Population | Adults with obesity (BMI ≥27) with or without type 2 diabetes |
| Doses studied | 1 mg, 4 mg, 8 mg, 12 mg weekly subcutaneous injection |
| Primary endpoint | Percent change in body weight from baseline |
| Highest dose result | ~24.2% mean weight reduction (12 mg) |
| Publication | New England Journal of Medicine (2023) |
| Phase 3 status (2026) | Ongoing |
Third-party HPLC tested, batch-matched COA. Same-day shipping before 3 PM CST from Wisconsin.
View GLP-3 RT →